Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

Adoptive T cell therapy (ACT) with expanded tumor-infiltrating lymphocytes (TIL) can induce durable responses in cancer patients from multiple histologies, with response rates of up to 50%. Antibodies blocking the engagement of the inhibitory receptor programmed cell death protein 1 (PD-1) have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamberlain, Christopher Aled, Bennett, Eric Paul, Kverneland, Anders Handrup, Svane, Inge Marie, Donia, Marco, Met, Özcan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807971/
https://www.ncbi.nlm.nih.gov/pubmed/35141398
http://dx.doi.org/10.1016/j.omto.2022.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807971/
https://www.ncbi.nlm.nih.gov/pubmed/35141398
http://dx.doi.org/10.1016/j.omto.2022.01.004

Ejemplares similares